The hidden institutional drivers powering today’s bull market might not end well for individual investors. Pay attention.

Amphastar Pharmaceuticals is rated a Buy, with ~81% upside to a $33 fair value, despite margin pressures for 2026. AMPH faces declining sales in legacy products but expects mid- to high-single-digit ...

An option is a financial instrument whose value is tied to an underlying asset; this is known as a derivative. Instead of buying an asset, such as company stock, outright, an options contract allows ...

Deep-pocketed investors have adopted a bearish approach towards Strategy (NASDAQ:MSTR), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled ...

The Defiance Nasdaq 100 Target 30 Income ETF offers a high current income yield (51.77% TTM) via a put-selling strategy on the Nasdaq-100 and US Treasuries, but caps upside potential. Most ...

A snapshot of the top strategies to make money from a highly volatile market Heading into the new year, traders expecting more volatile markets may want to refresh their approach. Discover the top ...